ReviewCellular and molecular life sciences : CMLS2010
Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.
Review in Cellular and molecular life sciences : CMLS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Non-Immunosuppressive Cyclophilin Inhibitors.Angewandte Chemie (International ed. in English) · 2022Review
- Review
- The spliceosomal proteins PPIH and PRPF4 exhibit bi-partite binding.The Biochemical journal · 2017Article
- Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities.Biomolecules · 2017Review
- A homolog of cyclophilin D is expressed inCell death discovery · 2017Article
- The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation.Journal of hepatology · 2016Article
- Targeting the cyclophilin domain of Ran-binding protein 2 (Ranbp2) with novel small molecules to control the proteostasis of STAT3, hnRNPA2B1 and M-opsin.ACS chemical neuroscience · 2015Article
- Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease.Scientific reports · 2015Article
- Differential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.The Journal of biological chemistry · 2014Article
- Cyclophilin A binds to the viral RNA and replication proteins, resulting in inhibition of tombusviral replicase assembly.Journal of virology · 2013Article
- Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Cellular and molecular life sciences : CMLS · 2013Review
- Heterogeneous susceptibility of circulating SIV isolate capsids to HIV-interacting factors.Retrovirology · 2013Article
- Advances in the current treatment of autoimmune hepatitis.Digestive diseases and sciences · 2012Review
- Cyclophilin involvement in the replication of hepatitis C virus and other viruses.Biological chemistry · 2012Review
- From Drosophila to humans: reflections on the roles of the prolyl isomerases and chaperones, cyclophilins, in cell function and disease.Journal of neurogenetics · 2012Review
- The TPR domain in the host Cyp40-like cyclophilin binds to the viral replication protein and inhibits the assembly of the tombusviral replicase.PLoS pathogens · 2012Article
- Human nucleoporins promote HIV-1 docking at the nuclear pore, nuclear import and integration.PloS one · 2012Article
- Synthesis of the C21-C34 fragment of antascomicin B.Tetrahedron letters · 2011Article
- The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.PLoS pathogens · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Cyclosporine A (CsA) is an immunosuppressive cyclic peptide that binds with a high affinity to 18 kDa human cyclophilin-A (hCyPA). CsA and its several natural derivatives have some pharmacological potential in treatment of diverse immune disorders. More than 20 paralogues of CyPA are expressed in the human body while expression levels and functions of numerous ORFs encoding cyclophilin-like sequences remain unknown. Certain derivatives of CsA devoid of immunosuppressive activity may have some potential in treatments of Alzheimer diseases, Hepatitis C and HIV infections, amyotrophic lateral sclerosis, congenital muscular dystrophy, asthma and various parasitic infections. Here, we discuss structural and functional aspects of the human cyclophilins and their interaction with various intra-cellular targets that can be under the control of CsA or its complexes with diverse cyclophilins that are selectively expressed in different cellular compartments. Some molecular aspects of the cyclophilins expressed in parasites invading humans and causing diseases were also analyzed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.